By Counterforce Health Team in Pomalyst (pomalidomide) —

How to Get Pomalyst (pomalidomide) Covered by Blue Cross Blue Shield in New Jersey: Complete Prior Authorization and Appeals Guide

Answer Box: Getting Pomalyst Covered by Blue Cross Blue Shield in New Jersey

Pomalyst (pomalidomide) requires prior authorization from Blue Cross Blue Shield plans in New Jersey for multiple myeloma treatment. To get approved: (1) Ensure your oncologist documents prior lenalidomide and proteasome inhibitor failures with progression within 60 days, (2) Complete mandatory POMALYST REMS enrollment for both patient and prescriber, and (3) Submit through Horizon BCBS's provider portal with ICD-10 code C90.0, dexamethasone combination plan, and medical necessity letter. If denied, New Jersey's Independent Health Care Appeals Program (IHCAP) offers free external review through Maximus within 4 months of internal denial.

Table of Contents

  1. Coding Basics: Medical vs. Pharmacy Benefit Paths
  2. ICD-10 Mapping for Multiple Myeloma and Kaposi Sarcoma
  3. Product Coding: HCPCS, J-Codes, and NDC Numbers
  4. Clean Prior Authorization Request Anatomy
  5. Frequent Coding and Submission Pitfalls
  6. Blue Cross Blue Shield New Jersey Verification Steps
  7. Pre-Submission Audit Checklist
  8. Appeals Process in New Jersey
  9. Cost-Saving Programs
  10. FAQ

Coding Basics: Medical vs. Pharmacy Benefit Paths

Pomalyst (pomalidomide) is an oral immunomodulatory drug that can be covered under either your pharmacy benefit or medical benefit, depending on how it's prescribed and administered.

Pharmacy Benefit (Most Common)

  • Coverage: Retail or specialty pharmacy dispensing
  • Billing: Uses NDC numbers and pharmacy claims processing
  • Typical for: Self-administered oral medications at home
  • Prior Auth: Required through pharmacy benefit management

Medical Benefit (Less Common)

  • Coverage: Physician office or hospital outpatient administration
  • Billing: Uses HCPCS J-codes on medical claims (CMS-1500 or UB-04)
  • Typical for: Buy-and-bill scenarios or administration oversight
  • Prior Auth: Required through medical benefit management
Tip: Most Blue Cross Blue Shield plans in New Jersey prefer pharmacy benefit coverage for oral oncology drugs like Pomalyst, but verify with your specific plan's formulary.

ICD-10 Mapping for Multiple Myeloma and Kaposi Sarcoma

Accurate diagnosis coding is critical for Pomalyst approval. Here are the primary ICD-10 codes:

Multiple Myeloma (Primary Indication)

  • C90.0: Multiple myeloma (general)
  • C90.00: Multiple myeloma not having achieved remission
  • C90.01: Multiple myeloma in remission
  • C90.02: Multiple myeloma in relapse

Kaposi Sarcoma (Secondary Indication)

  • C46.0: Kaposi's sarcoma of skin
  • C46.1: Kaposi's sarcoma of soft tissue
  • C46.9: Kaposi's sarcoma, unspecified

Documentation Requirements

Your medical records must clearly establish:

  • Pathology confirmation of diagnosis
  • Disease staging and current status
  • Prior treatment history with specific agents
  • Progression evidence within 60 days of last therapy

Product Coding: HCPCS, J-Codes, and NDC Numbers

HCPCS/J-Code Information

Pomalyst lacks a specific HCPCS J-code. Use these alternatives:

Code Description Use Case
J8999 Prescription drug, oral, chemotherapeutic, NOS Physician office billing
C9399 Unclassified drugs or biologicals Hospital outpatient use

NDC Numbers (Examples)

NDC numbers vary by strength and package size. Common examples include:

  • 1mg capsules: Verify current NDC through BMS Access Support
  • 2mg capsules: Contact wholesaler for active numbers
  • 3mg capsules: Check with specialty pharmacy
  • 4mg capsules: Most common strength prescribed
Note: NDC numbers change periodically. Always verify current numbers through BMS Access Support at 1-888-423-5227.

Units and Billing

  • Standard dosing: 4mg daily, days 1-21 of 28-day cycle
  • Billing units: Typically per capsule or per cycle
  • Quantity limits: Usually 21 capsules per 28-day period

Clean Prior Authorization Request Anatomy

A successful Pomalyst prior authorization includes these essential components:

Patient Information Section

  • Full name, date of birth, member ID
  • Contact information and preferred communication method
  • Primary care physician and referring oncologist details

Clinical Information Section

  • Primary diagnosis: ICD-10 code C90.0 (multiple myeloma)
  • Treatment history: Detailed timeline of prior therapies
  • Current status: Disease progression documentation
  • Proposed treatment: Pomalyst 4mg + dexamethasone regimen

Supporting Documentation

  1. Medical necessity letter from oncologist
  2. REMS enrollment confirmation for patient and prescriber
  3. Prior therapy failure documentation (lenalidomide + proteasome inhibitor)
  4. Recent lab results (CBC, comprehensive metabolic panel)
  5. Imaging studies showing disease progression

Example Medical Necessity Letter Structure

Patient: [Name], DOB: [Date], Member ID: [Number]
Diagnosis: Relapsed/refractory multiple myeloma (ICD-10: C90.0)

Treatment Request: Pomalyst (pomalidomide) 4mg daily, days 1-21/28-day cycle 
with dexamethasone 40mg weekly

Prior Therapy History:
- Lenalidomide + dexamethasone: [dates], discontinued due to progression
- Bortezomib-based therapy: [dates], discontinued due to progression
- Disease progression documented within 60 days of last therapy

Medical Necessity: Patient meets FDA-approved indications for Pomalyst...
[Continue with clinical rationale]

Frequent Coding and Submission Pitfalls

Common Mistakes to Avoid

Pitfall Impact Solution
Missing REMS enrollment Automatic denial Complete enrollment before PA submission
Incomplete prior therapy documentation Medical necessity denial Provide detailed timeline with progression dates
Wrong prescriber specialty Policy violation Ensure oncologist or hematologist prescribes
Missing dexamethasone plan Incomplete regimen Include combination therapy details
Outdated NDC numbers Processing delays Verify current numbers with manufacturer

Documentation Gaps That Cause Denials

  • Insufficient evidence of lenalidomide failure
  • Missing proteasome inhibitor trial documentation
  • Lack of progression evidence within 60-day window
  • Incomplete REMS paperwork
  • Non-specialist prescriber

Blue Cross Blue Shield New Jersey Verification Steps

Before Submitting Your Request

  1. Check formulary status using Horizon BCBS drug search tool
  2. Verify prior authorization requirements on the PA medicine list
  3. Confirm provider network status for prescribing oncologist
  4. Review quantity limits and refill restrictions

Submission Channels

  • Online portal: Preferred method for tracking and updates
  • Fax submission: Check provider manual for current numbers
  • Phone support: Provider services for urgent cases

Timeline Expectations

  • Standard review: 5-7 business days
  • Expedited review: 24-48 hours (with clinical urgency documentation)
  • Complex cases: Up to 14 days with additional information requests

Pre-Submission Audit Checklist

Before submitting your Pomalyst prior authorization, verify:

Clinical Requirements ✓

  • Multiple myeloma diagnosis confirmed with pathology
  • Prior lenalidomide therapy documented with failure/progression
  • Prior proteasome inhibitor therapy documented with failure/progression
  • Disease progression within 60 days of last therapy
  • Current lab values within acceptable ranges
  • Oncologist/hematologist prescriber

Administrative Requirements ✓

  • REMS enrollment completed for patient and prescriber
  • Patient-Physician Agreement signed
  • Pregnancy testing/contraception documented (if applicable)
  • Insurance eligibility verified
  • Prior authorization form completed
  • All supporting documents attached

Coding Accuracy ✓

  • Correct ICD-10 code (C90.0 for multiple myeloma)
  • Appropriate HCPCS code (J8999 for medical benefit)
  • Current NDC number verified
  • Accurate dosing and quantity requested
  • Dexamethasone combination therapy included

Appeals Process in New Jersey

If your Pomalyst prior authorization is denied, New Jersey offers robust appeal rights:

Internal Appeals (Blue Cross Blue Shield)

  • First level: Standard appeal within 180 days
  • Second level: If required by plan, additional internal review
  • Expedited: 72 hours for urgent cases
  • Peer-to-peer: Request physician-to-physician discussion

External Review (IHCAP)

New Jersey's Independent Health Care Appeals Program provides free external review:

  • Eligibility: After completing internal appeals
  • Timeline: File within 4 months of final internal denial
  • Administrator: Maximus Federal Services
  • Process: Independent medical experts review denial
  • Cost: Free to patients
  • Decision: Binding on insurance plan
From our advocates: We've seen multiple myeloma patients successfully overturn Pomalyst denials through IHCAP by submitting comprehensive treatment timelines and NCCN guideline references. The key is demonstrating clear progression after standard therapies and meeting FDA-approved criteria. While we can't guarantee outcomes, thorough documentation significantly improves your chances.

How to File External Appeal

  1. Download forms from NJ DOBI website
  2. Complete application with detailed medical information
  3. Attach denial letters from internal appeals
  4. Submit to Maximus via online portal or mail
  5. Await decision within 45 days (expedited cases faster)

Contact Maximus IHCAP at 1-888-393-1062 for forms and guidance.

Cost-Saving Programs

Manufacturer Support (Bristol Myers Squibb)

  • BMS Access Support: 1-888-423-5227
  • Services: Benefits verification, prior authorization assistance, appeals support
  • Patient assistance: Free drug program for eligible uninsured/underinsured patients
  • Copay cards: May reduce out-of-pocket costs for commercially insured patients

Foundation Grants

  • Leukemia & Lymphoma Society: Patient financial aid program
  • CancerCare: Financial assistance for cancer-related expenses
  • Patient Advocate Foundation: Copay relief program

State Programs

  • New Jersey Cancer Education and Early Detection Program: Resource referrals
  • NJ FamilyCare: Medicaid expansion coverage for eligible individuals

FAQ

How long does Blue Cross Blue Shield prior authorization take in New Jersey?

Standard prior authorization reviews take 5-7 business days. Expedited reviews for urgent cases are completed within 24-48 hours. Complex cases requiring additional information may take up to 14 days.

What if Pomalyst is not on my Blue Cross Blue Shield formulary?

You can request a formulary exception by demonstrating medical necessity. Submit documentation showing why formulary alternatives are inappropriate, including prior therapy failures or contraindications.

Can I request an expedited appeal if denied?

Yes, if delaying treatment would jeopardize your health. Document the clinical urgency and submit through expedited channels. Oncology cases often qualify for expedited review.

Does step therapy apply to Pomalyst in New Jersey?

Blue Cross Blue Shield plans may require step therapy, but New Jersey law provides exemptions for stage IV cancers, including advanced multiple myeloma. Reference this exemption in your prior authorization request.

What counts as prior therapy failure for Pomalyst approval?

You must have tried and failed (or been intolerant to) both lenalidomide and at least one proteasome inhibitor (bortezomib, carfilzomib, or ixazomib), with disease progression within 60 days of your last therapy.

How much does Pomalyst cost without insurance in New Jersey?

Retail cash prices often exceed $23,000 for a 21-capsule pack (one treatment cycle). Costs vary by pharmacy and strength. Contact BMS Access Support for patient assistance programs if uninsured.

Can my oncologist file an external appeal on my behalf?

Yes, healthcare providers can file IHCAP external appeals with written patient consent. This is often helpful since providers understand the clinical criteria and appeal process.

What happens if IHCAP overturns my denial?

The decision is legally binding. Blue Cross Blue Shield must authorize coverage and pay for your Pomalyst treatment within 10 business days of the IHCAP decision.

How Counterforce Health Helps

Navigating insurance approvals for specialty cancer medications like Pomalyst can be overwhelming, especially when you're already managing a serious diagnosis. Counterforce Health specializes in turning insurance denials into successful appeals by analyzing denial letters, plan policies, and clinical notes to create targeted, evidence-backed responses. Our platform identifies the specific denial basis—whether it's missing prior authorization criteria, step therapy requirements, or "not medically necessary" determinations—and drafts point-by-point rebuttals aligned with your plan's own rules.

For Pomalyst cases, Counterforce Health pulls the right evidence from FDA labeling, peer-reviewed studies, and specialty guidelines like NCCN, weaving them into appeals with all required clinical facts: your multiple myeloma diagnosis with ICD-10 codes, prior lenalidomide and proteasome inhibitor trials and failures, contraindications, and treatment goals. We understand the operational details payers expect, including REMS enrollment confirmation and combination therapy plans with dexamethasone.

Sources & Further Reading

Disclaimer: This guide provides general information about insurance coverage and is not medical advice. Always consult with your healthcare provider about treatment decisions and work with your insurance plan directly for coverage determinations. Coverage policies vary by plan and individual circumstances. For personalized assistance with your specific situation, contact your Blue Cross Blue Shield member services or consult with a patient advocate.

Powered by Counterforce Health—AI that turns drug denials into evidence-based appeals patients and clinicians can submit today.